Sort   by:  
 Page size 
UnknownEffective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Not available
S-EPMC9561555 | biostudies-literature
UnknownOutcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Not available
S-EPMC10345960 | biostudies-literature
UnknownFixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Not available
S-EPMC11022982 | biostudies-literature
UnknownIbrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Not available
S-EPMC8713593 | biostudies-literature
UnknownThe Effects of Forest Harvesting on Total and Methylmercury Concentrations in Surface Waters Depend on Harvest Practices and Physical Site Characteristics.
Not available
S-EPMC12329714 | biostudies-literature
UnknownTumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Not available
S-EPMC8020996 | biostudies-literature
UnknownOutcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Not available
S-EPMC7552812 | biostudies-literature
UnknownReal-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Not available
S-EPMC6119152 | biostudies-literature
UnknownOutcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Not available
S-EPMC11842760 | biostudies-literature
UnknownAssessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Not available
S-EPMC8588795 | biostudies-literature
Sort   by:  
 Page size